Related Experiment Video

Updated: Jul 5, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K

GPCR Inhibition in Treating Lymphoma

Marilia Barreca1, Virginia Spanò1, Maria V Raimondi1

  • 1Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.

ACS Medicinal Chemistry Letters
|January 19, 2024
PubMed

Insights

G protein-coupled receptors (GPCRs) are implicated in cancer, particularly lymphomas. This review focuses on synthetic strategies for GPCR inhibitors, especially CXCR4 inhibitors, for cancer treatment.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • G protein-coupled receptors (GPCRs) are crucial cell surface receptors regulating physiological functions.
  • Aberrant GPCR signaling pathways are frequently observed in various cancers, driving proliferation, angiogenesis, and metastasis.
  • GPCR alterations are increasingly recognized in different lymphoma subtypes.

Purpose of the Study:

  • To review synthetic strategies for developing GPCR inhibitors.
  • To highlight CXCR4 inhibitors as a significant class for cancer therapy, particularly lymphomas.

Main Methods:

  • Literature review of synthetic strategies for GPCR inhibitors.
  • Focus on CXCR4 inhibitors and their relevance in cancer and lymphoma treatment.

Main Results:

  • GPCRs play a significant role in cancer development and progression.
  • CXCR4 inhibitors are a promising therapeutic avenue, with many in market or preclinical development for these diseases.

Conclusions:

  • Targeting GPCRs, especially CXCR4, offers a viable strategy for cancer and lymphoma treatment.
  • Continued research into synthetic strategies for GPCR inhibitors is essential for advancing oncology therapeutics.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K